​

Cidara Therapeutics (CDTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

CDTX Stock Forecast

Cidara Therapeutics (CDTX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $156.75, with a high of $173.00 and a low of $137.00. This represents a 49.09% increase from the last price of $105.14.

- $40 $80 $120 $160 $200 High: $173 Avg: $156.75 Low: $137 Last Closed Price: $105.14

CDTX Stock Rating

Cidara Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 1 Strong Buy (9.09%), 10 Buy (90.91%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 10 1 Strong Sell Sell Hold Buy Strong Buy

CDTX Price Target Upside V Benchmarks

TypeNameUpside
StockCidara Therapeutics49.09%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2610
Avg Price Target$161.50$148.33$112.30
Last Closing Price$105.14$105.14$105.14
Upside/Downside53.60%41.08%6.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2542---6
Sep, 2542---6
Aug, 2542---6
Jul, 2542---6
Jun, 2532---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 09, 2025Sara NikH.C. Wainwright$150.00$108.1838.66%42.67%
Oct 03, 2025JMP Securities$173.00$98.5075.63%64.54%
Sep 26, 2025H.C. Wainwright$110.00$86.6027.02%4.62%
Sep 24, 2025Roy BuchananJMP Securities$153.00$88.3273.23%45.52%
Sep 24, 2025Seamus FernandezGuggenheim$167.00$86.6892.66%58.84%
Sep 24, 2025Brian AbrahamsRBC Capital$137.00$88.5854.66%30.30%
Jul 09, 2025Seamus FernandezGuggenheim$69.00$50.9635.40%-34.37%
Jun 24, 2025Guggenheim$68.00$46.8445.18%-35.32%
May 16, 2025Seamus FernandezGuggenheim$50.00$25.5096.08%-52.44%
Mar 12, 2025Roy BuchananJMP Securities$46.00$21.00119.05%-56.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2025H.C. WainwrightBuyBuyhold
Oct 21, 2025CitigroupMarket OutperformMarket Outperformhold
Sep 24, 2025CitigroupOutperformOutperformhold
Sep 24, 2025NeedhamBuyBuyhold
Sep 24, 2025GuggenheimBuyBuyhold
Sep 24, 2025H.C. WainwrightBuyBuyhold
Sep 24, 2025RBC CapitalOutperformOutperformhold
Sep 22, 2025WBB SecuritiesStrong BuyStrong Buyhold
Aug 08, 2025NeedhamBuyBuyhold
Aug 08, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-34.83$-16.75$-8.53$-5.25$-26.82----
Avg Forecast$-30.90$-17.67$-8.33$-5.60$-24.17$-9.59$-9.50$-8.39$-4.60
High Forecast$-30.49$-17.43$-7.88$-5.60$-24.17$-9.59$-3.41$-3.06$-4.60
Low Forecast$-31.31$-17.90$-8.71$-5.60$-24.17$-9.59$-17.63$-17.31$-4.60
Surprise %12.72%-5.21%2.40%-6.25%10.96%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.07M$49.57M$64.29M$63.91M$1.27M----
Avg Forecast$18.53M$46.64M$64.69M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
High Forecast$18.72M$47.11M$66.96M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Low Forecast$18.35M$46.17M$61.97M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Surprise %-34.89%6.28%-0.62%6.07%-74.67%----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.37M$-43.91M$-29.80M$-22.93M$-170.29M----
Avg Forecast$-49.20M$-77.23M$-35.59M$-22.93M$-105.63M$-41.91M$-45.98M$-44.51M$-20.11M
High Forecast$-39.36M$-76.21M$-18.86M$-13.30M$-105.63M$-41.91M$-14.89M$-13.37M$-20.11M
Low Forecast$-59.04M$-78.24M$-52.32M$-32.57M$-105.63M$-41.91M$-77.07M$-75.65M$-20.11M
Surprise %47.10%-43.14%-16.27%-61.21%----

CDTX Forecast FAQ

Is Cidara Therapeutics stock a buy?

Cidara Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cidara Therapeutics is a favorable investment for most analysts.

What is Cidara Therapeutics's price target?

Cidara Therapeutics's price target, set by 11 Wall Street analysts, averages $156.75 over the next 12 months. The price target range spans from $137 at the low end to $173 at the high end, suggesting a potential 49.09% change from the previous closing price of $105.14.

How does Cidara Therapeutics stock forecast compare to its benchmarks?

Cidara Therapeutics's stock forecast shows a 49.09% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cidara Therapeutics over the past three months?

  • October 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cidara Therapeutics’s EPS forecast?

Cidara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-9.59, marking a -64.24% decrease from the reported $-26.82 in 2024. Estimates for the following years are $-9.5 in 2026, $-8.39 in 2027, and $-4.6 in 2028.

What is Cidara Therapeutics’s revenue forecast?

Cidara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $53.59M, reflecting a 4102.86% increase from the reported $1.28M in 2024. The forecast for 2026 is $132.54M, followed by $10.83M for 2027, and $62.41M for 2028.

What is Cidara Therapeutics’s net income forecast?

Cidara Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-41.907M, representing a -75.39% decrease from the reported $-170M in 2024. Projections indicate $-45.978M in 2026, $-44.51M in 2027, and $-20.108M in 2028.